| dc.contributor | Meza-Espinoza, J.P., Facultad de Medicina, Unidad Acad�mica de Ciencias de la Salud y Tecnolog�a, Universidad Aut�noma de Tamaulipas, Tamaulipas, Mexico, Divisi�n de Gen�tica, CIBO-IMSS, Universidad de Guadalajara, Sierra Mojada No. 800, 44340 Guadalajara, Jalisco, Mexico; Guti�rrez-Angulo, M., Divisi�n de Gen�tica, CIBO-IMSS, Universidad de Guadalajara, Sierra Mojada No. 800, 44340 Guadalajara, Jalisco, Mexico; V�zquez-C�rdenas, A., Divisi�n de Gen�tica, CIBO-IMSS, Universidad de Guadalajara, Sierra Mojada No. 800, 44340 Guadalajara, Jalisco, Mexico; Delgado-Lamas, J.L., Departamento de Hematolog�a, Hospital de Especialidades, CMNO-IMSS, Mexico; Esparza-Flores, M.A., Departamento de Hematolog�a, Hospital de Pediatr�a, CMNO-IMSS, Mexico; Gonz�lez-Garc�a, J.R., Divisi�n de Gen�tica, CIBO-IMSS, Universidad de Guadalajara, Sierra Mojada No. 800, 44340 Guadalajara, Jalisco, Mexico | |
| dc.description.abstract | RT-PCR studies in 93 patients with chronic myelogenous leukemia from the Mexican West were done in order to know the proportion of b2a2 and b3a2 BCR/ABL1 transcripts. Forty-five patients showed the b3a2 transcript (48%), 37 (40%) displayed the b2a2 and in 11 cases (12%) both transcripts were detected. Statistical analyses showed that these figures are in accordance with two of three similar studies realized in Mexican population. Moreover, significant differences were found among Mexican people and patients from other countries, namely Ecuador, England, Italy, Poland, Japan, and Thailand. Ecuadorian patients showed differences with all the populations analyzed. These variations could be due to a different genetic background. | |
